Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SPARC (osteonectin), cwcv and kazal like domains proteoglycan 2, also known as SPOCK2 or Testican-2, is a member of the SPARC family of calcium-binding proteoglycans predominantly located in the extracellular matrix (ECM). This protein's structure consists of several domains, including a follistatin-like domain, a thyroglobulin type-1 domain with a characteristic CWCV motif, and an acidic C-terminal region with glycosaminoglycan-binding sites. SPOCK2 is involved in neurogenesis, ECM assembly, collagen binding, and cell-matrix adhesion; it is also linked to conditions such as cancer and bronchopulmonary dysplasia. Although structurally homologous to some signaling and adhesion molecules, SPOCK2 itself is not currently considered a classical therapeutic target, like a receptor or enzyme. No drugs or reliable biomarker roles are described for SPOCK2 to date.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SPARC (osteonectin), cwcv and kazal like domains proteoglycan 2 (SPOCK2).